Sweden’s role in global pricing is being highlighted in a new LIF article.
LIF describes the us “most favored nations (mfn)” drug policy as linking us medicine prices to the lowest prices in a set of comparable countries, including Sweden.
The article states that Sweden is a small market with list prices 18% below the European average, and that this could make Sweden a “price anchor” that affects market conditions in the us-prompting companies to reconsider launches of new medicines.
Data cited (GlobalData):
-
Europe: medicine launches down 35% in the 10 months after mfn was presented (May 2025) vs the 10 months before.
-
Sweden: launches down 56% over the same comparison.
LIF’s request: the government should set up a task force with relevant parties to propose measures to secure access to new treatments and Sweden’s position as a life science nation. Lif also notes government actions already taken via assignments to TLV and a medicines inquiry.
